FIELD: chemistry.
SUBSTANCE: invention relates to a process for the preparation of teneligliptin, a compound of formula I, or a salt thereof, or a hydrate thereof. Process comprises a) reacting a compound of formula 11 with bis-(2-chloroethyl)amine, or an N-protected derivative thereof, or a salt thereof, to obtain a compound of formula Int-B, or an N-protected derivative thereof, or a salt thereof or a) reacting 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde, a compound of formula 30, with piperazine-1-carboxylic acid tert-butyl ester to obtain tert-butyl-4-(4-formyl-3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine-1-carboxylate, a compound of formula 31, which is then deprotected to obtain a compound of formula Int-B; b) reacting a compound of formula Int-B, or an N-protected derivative thereof, or a salt thereof with a compound of formula 13 to obtain a compound of formula 14 wherein R is an amino protecting group selected from the group consisting of aralkyl, acyl, lower alkoxycarbonyl, aralkyloxycarbonyl, lower alkanesulfonyl, arylsulfonyl, tri- (lower alkyl) silyl, triphosgene; and c) deprotecting the compound of formula 14 to produce teneligliptin, a compound of formula I, or a salt thereof or a hydrate thereof. Invention also relates to a process for the preparation of teneligliptin 2,5 hydrobromide hydrate, which comprises the crystallisation of teneligliptin 2,5 hydrobromide or a hydrate thereof from a solvent selected from the group consisting of methanol, n-butanol, t-butanol, dimethylacetamide, dimethylformamide, tetrahydrofuran, and mixtures thereof.
, , , , , .
EFFECT: processes according to the invention enables to obtain teneligliptin or its salts with high yields and purity.
8 cl, 5 dwg, 18 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS CONTAINING BENZOPIPERAZINE AS BROMODOMAIN BET INHIBITORS | 2014 |
|
RU2720237C2 |
ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
DOSAGE FORMS CONTAINING TENELIGLIPTIN OXALATE SALTS AND SOLVATES THEREOF | 2018 |
|
RU2742418C1 |
NOVEL INDOLYSIN COMPOUNDS, METHOD FOR PRODUCING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2014 |
|
RU2693629C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
AZASPIROALKANE DERIVATIVES METALLOPROTEASE INHIBITORS | 2004 |
|
RU2379303C2 |
QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USE THEREOF | 2012 |
|
RU2610262C2 |
CRYSTALLINE DERIVATIVES OF 1-METHYLCARBAPENEM | 2000 |
|
RU2214411C2 |
AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
Authors
Dates
2018-05-16—Published
2013-08-28—Filed